Small pieces of synthetic RNA trigger a RNA interference (RNAi) response that holds great therapeutic potential to treat a number of diseases, especially cancer and pandemic viruses. The problem is delivery -- it is extremely difficult to get RNAi drugs inside the cells in which they are needed. To overcome this hurdle, researchers at University of California, San Diego School of Medicine have developed a way to chemically disguise RNAi drugs so that they are able to enter cells. Once inside, cellular machinery converts these disguised drug precursors -- called siRNNs -- into active RNAi drugs. The technique will publish Nov. 17 in Nature Biotechnology.
Metastasis is bad news for cancer patients. Northwestern University scientists now have demonstrated a simple but powerful tool that can detect live cancer cells in the bloodstream, potentially long before the cells could settle somewhere in the body and form a dangerous tumor.
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP).
Months of dedication and hard work in science, technology, engineering and mathematics (STEM) paid off tonight for three students named National Finalists in the Siemens Competition in Math, Science & Technology, the nation’s premier research competition for high school students.
A urine-based test for early detection and monitoring of bladder cancer and a plan to develop nanoparticles to deliver chemotherapy drugs to bladder tissue are among the first round of projects awarded research grants by the Johns Hopkins Greenberg Bladder Cancer Institute.
Stanching the free flow of blood from an injury remains a holy grail of clinical medicine. Controlling blood flow is a primary concern and first line of defense for patients and medical staff in many situations, from traumatic injury to illness to surgery. If control is not established within the first few minutes of a hemorrhage, further treatment and healing are impossible.
RTI Surgical Inc.™ (RTI), a leading global surgical implant company, announced that The Journal of Spinal Disorders & Techniques published a study online highlighting nanOss® clinical data results. NanOss is an advanced bone graft substitute that is composed of nano-structured hydroxyapatite granules and an open structured engineered collagen carrier.
University of Arkansas for Medical Sciences (UAMS) researcher Vladimir Zharov, Ph.D., D.Sc., recently was awarded a $1.5 million R01 grant by the National Institutes of Health to investigate his diagnostic concept — “In vivo reading written in blood” — with new stimuli-responsive nanoparticles circulating in blood.
Kansas State University researchers have developed a patented method of keeping mosquitoes and other insect pests at bay.
Nanomedicine is offering patients a growing arsenal of therapeutic drugs for a variety of diseases but often at a cost of thousands of dollars a month. Generics could substantially reduce the price tag for patients -- if only there were a well-defined way to make and regulate them. An article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, details the challenges on the road to generic nanodrugs.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.